Can physicians discuss or recommend psilocybin services to patients?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

For licensed physicians and other healthcare providers in Oregon who want to know whether they can raise psilocybin services in clinical conversations, what that discussion can include, and where the legal limits are.

The short answer

Yes — as of January 1, 2026, licensed healthcare professionals regulated by seven specified Oregon boards are explicitly protected from professional discipline for discussing psilocybin services with their patients. HB 2387, signed in 2025 and operative January 1, 2026, codified this protection in ORS 475A.338. Before HB 2387, many healthcare providers were uncertain whether raising psilocybin services in a clinical conversation could expose them to board discipline for discussing a federally scheduled substance. That uncertainty has been resolved for professionals regulated by the seven identified boards. What has not changed is that a clinician cannot prescribe psilocybin, cannot represent it as a medical treatment, and cannot bill insurance for any psilocybin-related service.

Which providers are protected

The discussion protection applies to health care providers regulated by any of the seven boards named in HB 2387:

Oregon Board of Licensed Professional Counselors and Therapists
Oregon Board of Naturopathic Medicine
Oregon Board of Psychology
Oregon Medical Board
Oregon State Board of Nursing
State Board of Licensed Social Workers
State Board of Pharmacy

A healthcare professional regulated by one of these boards can discuss psilocybin services with patients without risk of board discipline for the discussion itself. Providers regulated by other boards — dentists, chiropractors, optometrists, and others — do not have the same explicit protection and should proceed with more caution until their board has addressed the question.

What the discussion protection covers

Under ORS 475A.338(2)(a), the protection covers discussing psilocybin services — specifically, services provided by a licensed psilocybin facilitator at a licensed Oregon service center — as a treatment option with a patient. The protection is specific to Oregon’s licensed program, not to psilocybin use generally.

A physician can explain that Oregon’s licensed psilocybin program exists, describe how it works, share what the research suggests about potential benefits for conditions the patient is experiencing, and point the patient toward licensed service centers or facilitators. That conversation is now explicitly protected. What the discussion protection does not cover: recommending or facilitating psilocybin use outside the licensed Oregon program, prescribing psilocybin (no prescription pathway exists), billing for any service related to psilocybin administration, or representing psilocybin services as a medical treatment.

What a clinical discussion can include

Within the scope of normal clinical practice, a healthcare provider discussing psilocybin services with a patient can cover:

That Oregon’s licensed program is available to any adult 21 or older without a diagnosis or referral, and what the program’s three session types involve — preparation, administration, and integration. What the current research suggests about psilocybin for the patient’s specific concerns — depression, anxiety, PTSD, end-of-life distress, substance use disorders — while being clear about what the evidence does and does not show. That services are entirely out-of-pocket, typically running between $1,200 and $3,000 per session, with no standard health insurance coverage. That the patient can find licensed service centers through the OPS Licensee Directory at oregon.gov/psilocybin. That certain health conditions and medications create contraindications or interactions worth reviewing before access.

The provider should not, consistent with both ORS 475A and their own professional standards, represent psilocybin services as treating, curing, or managing any condition, suggest the patient obtain psilocybin outside the licensed program, or bill any insurance for psilocybin-related clinical time as if it were a reimbursable psychedelic treatment.

Medication review before a patient accesses services

One of the most clinically valuable things a prescribing clinician can do is review a patient’s medication list before that patient accesses Oregon’s psilocybin program. The formal contraindications under OPS rules are narrow — lithium use within 30 days, current ideation of harm to self or others, history of diagnosis or treatment for active psychosis — but the clinical picture is more complex.

Lithium is excluded because of seizure risk in combination with psilocybin. SSRIs and SNRIs may attenuate psilocybin’s effects and carry theoretical serotonin syndrome risk in some combinations — up to 80% of Oregon clients may be on serotonergic medications. MAOIs carry significant interaction risk and typically require a washout period before psilocybin use. Anticonvulsant mood stabilizers may reduce effects. Antipsychotics — which are 5-HT2A antagonists — can significantly blunt psilocybin’s effects.

Facilitators are not permitted to diagnose or provide clinical advice about medication interactions — that falls outside facilitation scope. A prescribing clinician who reviews a patient’s medication list, discusses realistic expectations given those medications, and identifies any that require medical guidance before a session is providing a legitimate and valuable clinical service.

Referral practices

A physician who wants to support a patient’s access to Oregon’s psilocybin program can point the patient to the OPS Licensee Directory, which lists service centers and facilitators who have consented to public listing. The clinician can also encourage the patient to seek a facilitator whose background and approach fits the patient’s circumstances — facilitators vary in their experience with veterans, end-of-life clients, trauma histories, and other population-specific presentations.

A formal clinical referral letter is not required and has no defined role in the OPS intake process. The patient contacts the service center directly. A clinician who wants to communicate relevant clinical context to a facilitator can only do so with the patient’s explicit authorization — and the facilitator, not being a healthcare provider under HIPAA, handles that information under ORS 475A.450’s confidentiality framework rather than HIPAA’s.

Integration support after a session

A clinician can also provide clinical support to a patient after a psilocybin session. The OPS program’s post-session support consists of the facilitator’s optional integration session and the 72-hour contact attempt — neither of which is clinical. A patient who brings significant material from a psilocybin experience into subsequent clinical appointments is not unusual, and a clinician who understands what the patient underwent — and can work with integration-oriented content in a clinical context — provides meaningfully better care.

HB 2387 protects this clinical conversation the same way it protects pre-session discussion. A clinician whose patient has already accessed psilocybin services can openly discuss the experience, its effects, and any clinical concerns it raises without risk of board discipline for that discussion.

What physicians cannot do

No prescription pathway for psilocybin exists in Oregon or federally. A physician cannot prescribe psilocybin, authorize a patient to obtain it outside the licensed program, or provide documentation that functions as a referral into the licensed program. The patient accesses the program independently — the clinician’s role, however supportive, is advisory and clinical rather than gatekeeping.

A clinician also cannot provide services at a psilocybin session without an OPS facilitator license. Attending a session as a medical observer, providing clinical support during an administration session, or supervising a session without a facilitator license is not authorized by HB 2387 or any other provision of ORS 475A.

When public information may be enough

HB 2387 and ORS 475A.338 are publicly available through the Oregon Legislative Assembly. OPS publishes its Licensee Directory and program information at oregon.gov/psilocybin. The OPS quarterly data dashboard provides program-level outcomes data.

When you should speak with a lawyer

A clinician who holds a federal position, receives federal funding, or practices at a federally licensed facility should get specific legal advice before discussing psilocybin services with patients — HB 2387’s protections run against state board discipline, not federal regulatory consequences. A clinician regulated by a board not named in HB 2387 who wants to understand their exposure should consult an attorney before engaging in clinical psilocybin discussions. A clinician who has received or expects to receive a board inquiry about psilocybin-related conduct should retain counsel before responding.

You might also want to read

This article is for general informational purposes only and does not constitute legal advice. Laws and regulations governing psilocybin services change frequently. For advice about your specific situation, consult a licensed attorney.